Cargando…
A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)
Over the past few decades, advances in immunological knowledge have led to the identification of novel immune checkpoints, reinvigorating cancer immunotherapy. Immunotherapy, represented by immune checkpoint inhibitors, has become the leader in the precision treatment of cancer, bringing a new dawn...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Chongqing Medical University
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404877/ https://www.ncbi.nlm.nih.gov/pubmed/37554219 http://dx.doi.org/10.1016/j.gendis.2022.05.020 |